US-based clinical trial software company Clario has acquired WCG’s electronic clinical outcome assessment (eCOA) business, having agreed to acquire it earlier this year.
The acquisition aims to help Clario provide quality data across various therapeutic fields by expanding its offerings across trial design, centralised image analysis, COAs and regulatory guidance for complex clinical trials.
Go deeper with GlobalData
It is also intended to bolster the company’s range of data collection and analysis solutions, particularly in neuroscience drug development.
Clario CEO Chris Fikry said: “Along with our recent acquisition of neurology imaging analysis experts, NeuroRx, we are positioned to be the true leader in delivering endpoint data solutions to neuroscience clinical trials.
“Our clients now have access to the most reliable, high-quality data across multiple modalities and all major neuroscience endpoints.
“This will have wide-ranging benefits for our customers and to patients in this area of significant unmet medical need.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataClario eCOA business general manager and executive vice-president Terry Burke said: “WCG has made significant contributions to eCOA in neuroscience trials, and we have long respected their achievements in this space.
“We’ve planned a seamless integration with an aim on preserving what’s already working well — trials will continue uninterrupted, and the platforms and study teams customers rely on will remain in place.
“By bringing WCG’s eCOA professionals and scientific capabilities to Clario, we can deliver the high-quality data and scientific rigour needed to support new complex studies and to accelerate breakthrough therapies.”
Based in Pennsylvania, Clario provides support for several areas of neuroscience drug development, including trial design and protocol development, site selection and staff training, cardiac safety expertise, analysis of quantitative movement, and regulatory guidance.
The company has been jointly owned by private equity firms Astorg and Nordic Capital since 2019, with Cinven and Novo Holdings also backing it as minority shareholders.
